Cover Image
市場調查報告書

KunWha Pharmaceutical Co., Ltd.:產品平台分析

KunWha Pharmaceutical Co., Ltd. - Product Pipeline Review - 2014

出版商 Global Markets Direct 商品編碼 306088
出版日期 內容資訊 英文 28 Pages
訂單完成後即時交付
價格
Back to Top
KunWha Pharmaceutical Co., Ltd.:產品平台分析 KunWha Pharmaceutical Co., Ltd. - Product Pipeline Review - 2014
出版日期: 2014年06月15日 內容資訊: 英文 28 Pages
簡介

KunWha Pharmaceutical Co., Ltd.ha是製造各種治療領域處方藥的製藥企業。

本報告提供KunWha Pharmaceutical Co., Ltd.的治療藥開發平台現狀及各開發階段的比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,彙整最新的企業新聞和發表,後期階段及中止的計劃相關資訊等。

KunWha Pharmaceutical Co., Ltd.的基本資料

KunWha Pharmaceutical Co., Ltd.概要

  • 主要資訊
  • 企業資料

KunWha Pharmaceutical Co., Ltd.:R&D概要

  • 主要的治療範圍

KunWha Pharmaceutical Co., Ltd.:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 合作夥伴產品
    • 合作夥伴產品/聯合治療模式

KunWha Pharmaceutical Co., Ltd.:開發中產品概況

  • 最後階段的開發中產品
    • 登記前的產品/聯合治療模式
    • 第三階段的產品/聯合治療模式
  • 臨床實驗階段的開發中產品
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 藥物研發中的產品/聯合治療模式

KunWha Pharmaceutical Co., Ltd.:藥物簡介

  • fentanyl citrate
  • pregabalin ER
  • sarpogrelate SR
  • KW-21072
  • KW-21097

KunWha Pharmaceutical Co., Ltd.:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

KunWha Pharmaceutical Co., Ltd.:最近的開發平台趨勢

KunWha Pharmaceutical Co., Ltd.:總公司和子公司的所在地

附錄

目錄
Product Code: GMDHC05014CDB

Global Markets Direct's, 'KunWha Pharmaceutical Co., Ltd. - Product Pipeline Review - 2014', provides an overview of the KunWha Pharmaceutical Co., Ltd.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of KunWha Pharmaceutical Co., Ltd.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of KunWha Pharmaceutical Co., Ltd. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of KunWha Pharmaceutical Co., Ltd.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the KunWha Pharmaceutical Co., Ltd.'s pipeline products

Reasons to buy

  • Evaluate KunWha Pharmaceutical Co., Ltd.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of KunWha Pharmaceutical Co., Ltd. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the KunWha Pharmaceutical Co., Ltd.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of KunWha Pharmaceutical Co., Ltd. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of KunWha Pharmaceutical Co., Ltd.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of KunWha Pharmaceutical Co., Ltd. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • KunWha Pharmaceutical Co., Ltd. Snapshot
    • KunWha Pharmaceutical Co., Ltd. Overview
    • Key Information
    • Key Facts
  • KunWha Pharmaceutical Co., Ltd. - Research and Development Overview
    • Key Therapeutic Areas
  • KunWha Pharmaceutical Co., Ltd. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
  • KunWha Pharmaceutical Co., Ltd. - Pipeline Products Glance
    • KunWha Pharmaceutical Co., Ltd. - Late Stage Pipeline Products
      • Pre-Registration Products/Combination Treatment Modalities
      • Phase III Products/Combination Treatment Modalities
    • KunWha Pharmaceutical Co., Ltd. - Clinical Stage Pipeline Products
      • Phase I Products/Combination Treatment Modalities
    • KunWha Pharmaceutical Co., Ltd. - Early Stage Pipeline Products
      • Discovery Products/Combination Treatment Modalities
  • KunWha Pharmaceutical Co., Ltd. - Drug Profiles
    • fentanyl citrate
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • pregabalin ER
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • sarpogrelate SR
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • KW-21072
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • KW-21097
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • KunWha Pharmaceutical Co., Ltd. - Pipeline Analysis
    • KunWha Pharmaceutical Co., Ltd. - Pipeline Products by Target
    • KunWha Pharmaceutical Co., Ltd. - Pipeline Products by Route of Administration
    • KunWha Pharmaceutical Co., Ltd. - Pipeline Products by Molecule Type
    • KunWha Pharmaceutical Co., Ltd. - Pipeline Products by Mechanism of Action
  • KunWha Pharmaceutical Co., Ltd. - Recent Pipeline Updates
  • KunWha Pharmaceutical Co., Ltd. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • KunWha Pharmaceutical Co., Ltd., Key Information
  • KunWha Pharmaceutical Co., Ltd., Key Facts
  • KunWha Pharmaceutical Co., Ltd. - Pipeline by Indication, 2014
  • KunWha Pharmaceutical Co., Ltd. - Pipeline by Stage of Development, 2014
  • KunWha Pharmaceutical Co., Ltd. - Monotherapy Products in Pipeline, 2014
  • KunWha Pharmaceutical Co., Ltd. - Partnered Products in Pipeline, 2014
  • KunWha Pharmaceutical Co., Ltd. - Partnered Products/ Combination Treatment Modalities, 2014
  • KunWha Pharmaceutical Co., Ltd. - Pre-Registration, 2014
  • KunWha Pharmaceutical Co., Ltd. - Phase III, 2014
  • KunWha Pharmaceutical Co., Ltd. - Phase I, 2014
  • KunWha Pharmaceutical Co., Ltd. - Discovery, 2014
  • KunWha Pharmaceutical Co., Ltd. - Pipeline by Target, 2014
  • KunWha Pharmaceutical Co., Ltd. - Pipeline by Route of Administration, 2014
  • KunWha Pharmaceutical Co., Ltd. - Pipeline by Molecule Type, 2014
  • KunWha Pharmaceutical Co., Ltd. - Pipeline Products by Mechanism of Action, 2014
  • KunWha Pharmaceutical Co., Ltd. - Recent Pipeline Updates, 2014
  • KunWha Pharmaceutical Co., Ltd., Other Locations

List of Figures

  • KunWha Pharmaceutical Co., Ltd. - Pipeline by Top 10 Indication, 2014
  • KunWha Pharmaceutical Co., Ltd. - Pipeline by Stage of Development, 2014
  • KunWha Pharmaceutical Co., Ltd. - Monotherapy Products in Pipeline, 2014
  • KunWha Pharmaceutical Co., Ltd. - Pipeline by Top 10 Target, 2014
  • KunWha Pharmaceutical Co., Ltd. - Pipeline by Top 10 Route of Administration, 2014
  • KunWha Pharmaceutical Co., Ltd. - Pipeline by Top 10 Molecule Type, 2014
  • KunWha Pharmaceutical Co., Ltd. - Pipeline Products by Top 10 Mechanism of Action, 2014
Back to Top